Abbott wins U.S. approval for test that can detect coronavirus in minutes
By Carl O'Donnell (Reuters) - Abbott Laboratories said on Friday it won U.S. marketing approval for a diagnostic test for the coronavirus that can deliver results to patients within minutes and be used in physicians offices and urgent care clinics, as well as hospitals. The United States now has more cases of the coronavirus than any other country, and hospitals have struggled to meet the demand to test thousands of people for the often-deadly virus.
coronavirus in minutes" src="https://images.firstpost.com/wp-content/uploads/reuters/03-2020/29/2020-03-28T171902Z_1_LYNXMPEG2R0JY_RTROPTP_2_MARKETS-STOCKS.jpg" alt="Abbott wins US approval for test that can detect coronavirus in minutes" width="300" height="225" />
By Carl O'Donnell
(Reuters) - Abbott Laboratories said on Friday it won U.S. marketing approval for a diagnostic test for the coronavirus that can deliver results to patients within minutes and be used in physicians offices and urgent care clinics, as well as hospitals.
The United States now has more cases of the coronavirus than any other country, and hospitals have struggled to meet the demand to test thousands of people for the often-deadly virus.
The U.S. Food and Drug Administration granted the approval under its Emergency Use Authorization.
Abbott said in a statement that it plans to begin distributing the test next week and will ramp up manufacturing to 50,000 tests per day.
"This is a significant leap forward," John Frels, vice president of research and development at Abbott, said in an interview with Reuters. "You can get a positive result in five minutes and a negative result in 13 minutes. You can walk into a clinic and literally get results while you are there."
The portable test will run on Abbott's ID NOW platform.
It is the second test to be approved by the FDA that can be used directly in physicians' offices and other community healthcare settings and promptly provide results to patients. Last week, the FDA approved a test made by Cepheid that can be used at the point of care.
"The COVID-19 pandemic will be fought on multiple fronts, and a portable molecular test that offers results in minutes adds to the broad range of diagnostic solutions needed to combat this virus," said Robert Ford, president and chief operating officer at Abbott, in a statement.
Abbott received approval last week for a high volume, automated diagnostic test that can be used in laboratories and said at the time it would immediately distribute 150,000 of the tests around the country.
Between the two platforms, Abbott said it plans to produce 5 million tests per month.
The FDA has been rushing to approve tests for the coronavirus on an emergency basis and has approved others made by companies including Roche Holding AG
With the expansion of testing has come a surge in confirmed cases of COVID-19 . Reuters reported on Friday that the United States now has more than 100,000 cases.
(Reporting by Carl O'Donnell; Editing by Leslie Adler)
This story has not been edited by Firstpost staff and is generated by auto-feed.
By Mike Spector and Jeffrey Dastin (Reuters) - The National Labor Relations Board has begun reviewing ballots from Amazon.com Inc's workers in Alabama, who have voted on whether to form a union, with momentum for future labour organizing at America's second-largest private employer hanging in the balance. Agents from the labour board began sifting through ballots sent to more than 5,800 workers at Amazon's Bessemer, Alabama-based warehouse at 10 a.m
By Elizabeth Culliford NEW YORK (Reuters) - Spotify Inc said on Tuesday it has purchased Betty Labs, the company behind sports-focused social audio app Locker Room, to accelerate its move into live audio. New voice-based platforms, including invite-only social app Clubhouse, have seen rapid growth in recent months during the COVID-19 pandemic.
By Devika Krishna Kumar NEW YORK (Reuters) - Oil prices slid on Tuesday as the Suez Canal reopened to traffic and the dollar rallied, while focus turned to an OPEC+ meeting this week, where analysts expect an extension to supply curbs to offset dim demand prospects. Brent crude fell $1.20, or 1.9%, at $63.78 a barrel by 1:12 p.m.